Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

G1 THERAPEUTICS, INC.

(GTHX)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietàFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su G1 THERAPEUTICS, INC.
20/10G1 THERAPEUTICS: to Provide Third Quarter 2021 Financial Results and Business Update on N..
15/10G1 THERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
15/10G1 Therapeutics, Inc. Announces Resignation of Seth A. Rudnick from Board of Directors
08/10G1 THERAPEUTICS: Retrospective analysis of pooled results from three studies shows cosela..
07/10Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilac..
07/10G1 Therapeutics, Inc. Announces Results from Retrospective Analysis of Pooled Results o..
01/10G1 THERAPEUTICS: Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10G1 THERAPEUTICS: Announces Permanent J-Code from Centers for Medicare and Medicaid Servic..
01/10NORTH AMERICAN MORNING BRIEFING: Fears Heighten -2-
16/09G1 THERAPEUTICS: Announces new supplemental cosela (trilaciclib) sales force
15/09G1 THERAPEUTICS: Announces New Supplemental COSELA™ (Trilaciclib) Sales Force (Form ..
15/09G1 THERAPEUTICS, INC.: Regulation FD Disclosure, Financial Statements and Exhibits (form ..
15/09G1 THERAPEUTICS: Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
15/09G1 Therapeutics Announces New Supplemental Cosela™ (Trilaciclib) Sales Force
06/09G1 THERAPEUTICS: Announces inducement grants under nasdaq listing rule 5635(4)
06/09G1 THERAPEUTICS: To participate in two upcoming september conferences
03/09G1 THERAPEUTICS: to Participate in Two Upcoming September Conferences
03/09G1 THERAPEUTICS: Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08G1 THERAPEUTICS: Granted new technology add-on payment for cosela by centers for medicare..
04/08G1 THERAPEUTICS: Provides Second Quarter 2021 Financial Results and Operational Highlight..
04/08G1 THERAPEUTICS: Management's Discussion and Analysis of Financial Condition and Results ..
04/08G1 THERAPEUTICS, INC.: Results of Operations and Financial Condition, Financial Statement..
04/08G1 THERAPEUTICS: Earnings Flash (GTHX) G1 THERAPEUTICS Posts Q2 Loss $-0.94, vs. Street E..
04/08G1 THERAPEUTICS: Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q2 Revenue $6.6M, vs. Stre..
04/08G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highligh..
04/08G1 Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
04/08G1 THERAPEUTICS: Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilacic..
04/08G1 Therapeutics Grants New Technology Add-On Payment for COSELA™ (Trilaciclib) by Cente..
04/08G1 Therapeutics Receives New Technology Add-On Payment for Cosela™ (Trilaciclib) by Cen..
02/08G1 THERAPEUTICS: Announces Appointment of Andrew Perry as Chief Commercial Officer (Form ..
02/08G1 THERAPEUTICS, INC.: Change in Directors or Principal Officers, Financial Statements an..
02/08G1 THERAPEUTICS: Announces Appointment of Andrew Perry as Chief Commercial Officer
02/08G1 Therapeutics, Inc. Announces Executive Changes
29/07G1 THERAPEUTICS: To provide second quarter 2021 financial results and business update on ..
28/07G1 THERAPEUTICS: to Provide Second Quarter 2021 Financial Results and Business Update on ..
20/07G1 THERAPEUTICS: Receives fast track designation from u.s. food and drug administration f..
19/07G1 THERAPEUTICS: Secures FDA Fast Track Designation for Breast Cancer Combo Therapy
19/07G1 THERAPEUTICS: Receives Fast Track Designation from U.S. Food and Drug Administration f..
19/07G1 Therapeutics, Inc. Receives Fast Track Designation from U.S. Food and Drug Administr..
19/07G1 Therapeutics Gets Fast Track Designation for Breast Cancer Treatment
05/07G1 THERAPEUTICS: Announces inducement grants under nasdaq listing rule 5635(4)
03/07G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07G1 THERAPEUTICS: Certificate of Correction to G1 Therapeutics, Inc.'s Amended and Restate..
02/07G1 THERAPEUTICS, INC.: Entry into a Material Definitive Agreement, Amendments to Articles..
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell Microcap Growth Index
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell 3000E Growth Index
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell Microcap Value Index
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell 3000E Index
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell 3000E Value Index
25/06G1 THERAPEUTICS, INC.(NASDAQGS: GTHX) added to Russell Microcap Index
21/06G1 THERAPEUTICS: Announces Addition of Alicia Secor to Board of Directors (Form 8-K)
21/06G1 THERAPEUTICS, INC.: Change in Directors or Principal Officers, Submission of Matters t..
21/06G1 THERAPEUTICS: Announces addition of alicia secor to board of directors
18/06G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
18/06G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
16/06G1 THERAPEUTICS: to Present at the 2021 Raymond James Human Health Innovation Conference
16/06ER+/ HER2-VE BREAST CANCER PIPELINE: Emerging Therapies and Key pharma players involved b..
15/06G1 THERAPEUTICS: Initiates preserve 3 a randomized phase 2 study of cosela in bladder can..
14/06G1 THERAPEUTICS: Commences Phase 2 Study of Cosela in Bladder Cancer
14/06G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (tril..
14/06G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA in Bladder C..
07/06G1 THERAPEUTICS: Presents data on cosela (trilaciclib) at asco on potential immune activa..
07/06G1 THERAPEUTICS: Presents phase 1 data at asco describing favorable safety profile and ev..
07/06G1 THERAPEUTICS: Announces inducement grants under nasdaq listing rule 5635(4)
04/06G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/06G1 THERAPEUTICS: Reports Positive Data From Phase 1 Study of Rintodestrant, Palbociclib C..
04/06G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and E..
04/06G1 Therapeutics Presents Phase 1 Data At ASCO Describing Favorable Safety Profile and E..
04/06G1 THERAPEUTICS: Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune..
04/06G1 Therapeutics Presents Data on COSELA at ASCO on Potential Immune Activation in Patie..
19/05G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (A..
17/05G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact ..
11/05G1 THERAPEUTICS: Initiates randomized double blind placebo controlled phase 2 study of co..
10/05G1 THERAPEUTICS: Kicks off Phase 2 Study Related to Treatment of NonSmall Cell Lung Cance..
10/05G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of C..
1  2  3  4  5Pross.
Prossimo evento su G1 THERAPEUTICS, INC.
03/11/21